IMCD unveiled 10 health formulations: IMCD stock sits 5.49 percent below its high

Published on 10/08/2026 at 12:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Operating EBITA rose 4.00 percent in first-half 2026. IMCD stock costs EUR 99.28 on October 8, 2026 after EUR 98.76.

Schwarzweiß-Dokumentarfoto von Arbeitern bei Kontrolle chemischer Lagertanks in Industriehalle — Schwarzweiß-Reportage dokumentiert Qualitätskontrolle bei IMCD N.V., ISIN NL0010801007, in chemischer Lagerhalle authentisch, Illustration mit AI erstellt.

IMCD stock (ISIN NL0010801007) was trading at EUR 99.28 at Lang & Schwarz on October 8, 2026 at 12:21 p.m. CEST, plus 0.53 percent versus the prior close of EUR 98.76. The company had unveiled 10 ready-to-market women health formulations on October 1, 2026, according to Simply Wall St.

Ten formulations target health demand

The portfolio covers menopause, hormonal balance, inner wellness, age preservation and cognitive support. The initiative places IMCD's specialty-ingredient distribution business closer to finished formulation solutions, a shift that can increase the value of its supplier and customer relationships.

The event took place at Vitafoods Asia 2026, where IMCD presented the formulations as ready-to-market products rather than as a single new customer contract. That distinction matters: the announcement expands the commercial offering, while future revenue conversion will depend on customer uptake and regional demand.

Operating growth supports the story

Operating EBITA increased 4.00 percent in the first half of 2026, according to Simply Wall St. The period also included revenue growth from organic expansion and acquisitions, giving the women health push a broader operating context than a standalone product announcement.

IMCD's market capitalization was EUR 5.8 billion on October 8, 2026. Its 52-week range was EUR 68.14 to EUR 105.05, putting the Lang & Schwarz price 5.49 percent below the high and 45.72 percent above the low.

November results set the next test

IMCD is scheduled to publish its first nine months 2026 results on November 5, 2026, according to its investor-relations calendar. The report should show whether the company's specialty mix and formulation activity are translating into volume and margin progress beyond the first half.

At Lang & Schwarz, IMCD stock was trading at EUR 99.28 on October 8, 2026 at 12:21 p.m. CEST, plus 0.53 percent versus the Lang & Schwarz prior close of EUR 98.76. The further course of trading is shown by the continuously updated real-time quote of IMCD stock.